ACRV
ACRV
NASDAQ · Biotechnology

Acrivon Therapeutics Inc

$1.79
-0.13 (-6.77%)
As of May 16, 2:19 AM ET ·
Analyst Consensus
Strong Buy
14
Analysts
Moderate
Coverage
Buy 13 93%
Hold 1 7%
Sell 0 0%
Price Target
Analyst Price Target +2,280.4% upside
Low Target $22.54
Average Target $42.61
High Target $49.20
Current Price $1.79
Current
$1.79
Target
$42.61
$22.54 $42.61 avg $49.20
Scenario Analysis
Bear Case
$22.54
1,159.2%
Low target
Base Case
$42.61
+2,280.4%
Avg target
Bull Case
$49.20
+2,648.6%
High target
Risk/Reward
2.3x
Favorable
Price in Context
52-Week High
$3.56
-49.7% from high
52-Week Low
$1.05
+70.5% from low
Target vs 52W High
$42.61
+1,096.9% vs high
Next Earnings Report
May 20, 2026
2d
until earnings
EPS Est: $-0.54
Earnings in 2 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 40 75% $257.58 +22.4%
AMGN
Amgen Inc
Hold 44 48% $190.87 -41.5%
GILD
Gilead Sciences Inc
Strong Buy 39 79% $362.68 +179.9%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 79% $438.34 +0.3%
REGN
Regeneron Pharmaceuticals
Strong Buy 38 79% $76.80 -89.0%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 75% $102.31 -64.3%
RVMD
Revolution Medicines Inc
Strong Buy 27 96% $114.11 -21.7%
BIIB
Biogen Inc
Buy 43 56% $91.45 -52.6%